Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Misses on EPS, Stock Up 0.89%

Arrowhead Pharmaceuticals reported a loss per share that was worse than expected, but the stock still managed to rise by 0.89%. This increase may indicate that investors are optimistic about the company's future despite the earnings miss. The lack of revenue data and management commentary leaves some uncertainty about the company's current performance and outlook.